Skip to main content

Mumps and ovarian cancer: modern interpretation of an historic association

Cancer Causes & Control volume 21, pages 1193–1201 (2010)Cite this article

Abstract

Background

Epidemiologic studies found childhood mumps might protect against ovarian cancer. To explain this association, we investigated whether mumps might engender immunity to ovarian cancer through antibodies against the cancer-associated antigen MUC1 abnormally expressed in the inflamed parotid gland.

Methods

Through various health agencies, we obtained sera from 161 cases with mumps parotitis. Sera were obtained from 194 healthy controls. We used an ELISA to measure anti-MUC1 antibodies and electro-chemiluminescence assays to measure MUC1 and CA 125. Log-transformed measurements were analyzed by t-tests, generalized linear models, and Pearson or Spearman correlations. We also conducted a meta-analysis of all published studies regarding mumps and ovarian cancer.

Results

Adjusting for assay batch, age, and sex, the level of anti-MUC1 antibodies was significantly higher in mumps cases compared to controls (p = 0.002). Free circulating levels of CA 125, but not MUC1, were also higher in cases (p = 0.02). From the meta-analysis, the pooled odds ratio estimate (and 95% CI) for the mumps and ovarian cancer association was 0.81 (0.68–0.96) (p = 0.01).

Conclusion

Mumps parotitis may lead to expression and immune recognition of a tumor-associated form of MUC1 and create effective immune surveillance of ovarian cancer cells that express this form of MUC1.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. West RO (1966) Epidemiology study of malignancies of the ovaries. Cancer 19:1001–1007

    Article  CAS  PubMed  Google Scholar 

  2. Wynder EL, Dodo H, Barber HR (1969) Epidemiology of cancer of the ovary. Cancer 23(2):352–370

    Article  CAS  PubMed  Google Scholar 

  3. Newhouse ML, Pearson RM, Fullerton JM, Boesen EA, Shannon HS (1977) A case control study of carcinoma of the ovary. Br J Prev Soc Med 31(3):148–153

    CAS  PubMed  Google Scholar 

  4. Menczer J, Modan M, Ranon L, Golan A (1979) Possible role of mumps virus in the etiology of ovarian cancer. Cancer 43(4):1375–1379

    Article  CAS  PubMed  Google Scholar 

  5. Golan A, Joosting AC, Orchard ME (1979) Mumps virus and ovarian cancer. S Afr Med J 56(1):18–20

    CAS  PubMed  Google Scholar 

  6. Cramer DW, Welch WR, Cassells S, Scully RE (1983) Mumps, menarche, menopause, and ovarian cancer. Am J Obstet Gynecol 147(1):1–6

    CAS  PubMed  Google Scholar 

  7. Schiffman MH, Hartge P, Lesher LP, McGowan L (1985) Mumps and postmenopausal ovarian cancer. Am J Obstet Gynecol 152(1):116–118

    CAS  PubMed  Google Scholar 

  8. Chen Y, Wu PC, Lang JH et al (1992) Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 21(1):23–29

    Article  CAS  PubMed  Google Scholar 

  9. Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122(1):170–176

    Article  CAS  PubMed  Google Scholar 

  10. Cramer DW, Titus-Ernstoff L, McKolanis JR et al (2005) Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 14(5):1125–1131

    Article  CAS  PubMed  Google Scholar 

  11. Hamanaka Y, Suehiro Y, Fukui M et al (2003) Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 103(1):97–100

    Article  CAS  PubMed  Google Scholar 

  12. Alos L, Lujan B, Castillo M et al (2005) Expression of membrane-bound mucins (MUC1 and MUC4) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC7) in mucoepidermoid carcinomas of salivary glands. Am J Surg Pathol 29(6):806–813

    Article  PubMed  Google Scholar 

  13. Fichorova RN, Richardson-Harman N, Alfano M et al (2008) Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem 80(12):4741–4751

    Article  CAS  PubMed  Google Scholar 

  14. Egger M, Smith G, Altman D (2001) Systematic reviews in health care: meta-analysis in context, 2nd edn. BMJ Publishing Group, London

    Google Scholar 

  15. Baldus SE, Engelmann K, Hanisch FG (2004) MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 41(2):189–231

    Article  CAS  PubMed  Google Scholar 

  16. Vlad AM, Finn OJ (2004) Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis 20:73–79

    CAS  PubMed  Google Scholar 

  17. Campbell BJ, Yu LG, Rhodes JM (2001) Altered glycosylation in inflammatory bowel disease: a possible role in cancer development. Glycoconj J 18(11–12):851–858

    Article  CAS  PubMed  Google Scholar 

  18. Jerome KR, Kirk AD, Pecher G, Ferguson WW, Finn OJ (1997) A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol Immunother 43(6):355–360

    Article  CAS  PubMed  Google Scholar 

  19. Nakajima M, Manabe T, Niki Y, Matsushima T (1998) Serum KL-6 level as a monitoring marker in a patient with pulmonary alveolar proteinosis. Thorax 53(9):809–811

    Article  CAS  PubMed  Google Scholar 

  20. Takaishi H, Ohara S, Hotta K et al (2000) Circulating autoantibodies against purified colonic mucin in ulcerative colitis. J Gastroenterol 35(1):20–27

    Article  CAS  PubMed  Google Scholar 

  21. Kohno N (1999) Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest 46:151–158

    CAS  PubMed  Google Scholar 

  22. Vlad AM, Muller S, Cudic M et al (2002) Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 196(11):1435–1446

    Article  CAS  PubMed  Google Scholar 

  23. Okamura K, Kiyoshima T, Shima K et al (2002) Immunohistochemical expression of CA19-9 and CA125 in mucoepidermoid and adenoid cystic carcinomas of the salivary gland. Oral Oncol 38(3):244–250

    Article  CAS  PubMed  Google Scholar 

  24. Mink PJ, Sherman ME, Devesa SS (2002) Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978–1998. Cancer 95(11):2380–2389

    Article  PubMed  Google Scholar 

  25. Tipples G, Beirnes J, Hiebert J et al (2008) Laboratory guidelines for the diagnosis of mumps v.3 (3 April 2008), http://www.nml-lnm.gc.ca/guide/docs/Mumps_Lab_guide.pdf. Accessed 14 July 2009

  26. Jin L, Beard S, Brown DW (1999) Genetic heterogeneity of mumps virus in the United Kingdom: identification of two new genotypes. J Infect Dis 180(3):829–833

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Claudia Krause, Bernard Johnson, and Michael Trythall for helping us assemble the specimen sets and for their thoughtful comments on the manuscript and Huaiping Yan and Vanessa Tang-Fernandez for laboratory assistance. Grants: US Department of Defense #W81XWH-07-1-0292 and NIH Grant R01CA123170.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology Epidemiology Center, Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital (BWH), Harvard Medical School, 221 Longwood Ave, RFB 366, Boston, MA, 02115, USA

    Daniel W. Cramer & Allison F. Vitonis

  2. US Food and Drug Administration, Silver Spring, MD, USA

    Simone P. Pinheiro

  3. Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    John R. McKolanis & Olivera J. Finn

  4. Laboratory of Genital Tract Biology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Raina N. Fichorova

  5. Centre for Infections, Health Protection Agency, London, UK

    Kevin E. Brown

  6. Division of Microbiology, Department of Pathology and Laboratory Medicine, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

    Todd F. Hatchette

  7. Department of Pathology, Dalhousie University, Halifax, NS, Canada

    Todd F. Hatchette

Authors
  1. Daniel W. Cramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Allison F. Vitonis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Simone P. Pinheiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John R. McKolanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raina N. Fichorova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kevin E. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Todd F. Hatchette
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Olivera J. Finn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel W. Cramer.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cramer, D.W., Vitonis, A.F., Pinheiro, S.P. et al. Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes Control 21, 1193–1201 (2010). https://doi.org/10.1007/s10552-010-9546-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-010-9546-1

Keywords

  • Ovarian cancer
  • Mumps parotitis
  • MUC1
  • CA125